4.7 Article

Loss of the Rho GTPase activating protein p190-B enhances hematopoietic stem cell engraftment potential

Journal

BLOOD
Volume 114, Issue 17, Pages 3557-3566

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-02-205815

Keywords

-

Categories

Funding

  1. Board of Trustee Cincinnati Children's Hospital Medical Center Award (M.-D.F.)
  2. American Heart Association Scientific and Development
  3. National Institutes of Health [DK62757]

Ask authors/readers for more resources

Hematopoietic stem cell (HSC) engraftment is a multistep process involving HSC homing to bone marrow, self-renewal, proliferation, and differentiation to mature blood cells. Here, we show that loss of p190-B RhoGTPase activating protein, a negative regulator of Rho GTPases, results in enhanced long-term engraftment during serial transplantation. This effect is associated with maintenance of functional HSC-enriched cells. Furthermore, loss of p190-B led to marked improvement of HSC in vivo repopulation capacity during ex vivo culture without altering proliferation and multilineage differentiation of HSC and progeny. Transcriptional analysis revealed that p190-B deficiency represses the up-regulation of p16(Ink4a) in HSCs in primary and secondary transplantation recipients, providing a possible mechanism of p190-B-mediated HSC functions. Our study defines p190-B as a critical transducer element of HSC self-renewal activity and long-term engraftment, thus suggesting that p190-B is a target for HSC-based therapies requiring maintenance of engraftment phenotype. (Blood. 2009;114:3557-3566)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available